Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
ALK tyrosine kinase inhibitor

Alunbrig (brigatinib)

An approved treatment for ALK-Positive Lung Cancer.

FDA Approved (2017)by Takeda Pharmaceuticals (discovered by ARIAD Pharmaceuticals)
Preclinical
Phase 1
Phase 2
Phase 3
Approved
2017

Drug facts

The same compound appears under different names depending on the context. Here is how to identify Brigatinib wherever you encounter it, plus the key facts at a glance.

Generic name
Brigatinib
Brand name
Alunbrig
Development code
AP26113
Drug class
ALK tyrosine kinase inhibitor
Manufacturer
Takeda Pharmaceuticals (discovered by ARIAD Pharmaceuticals)
How it's taken
Oral tablets, once a day

Alunbrig (brigatinib) is a pill taken once a day for adults with ALK-positive non-small cell lung cancer, found with an FDA-approved test.

  • It is for cancer that has spread to other parts of the body (metastatic)[1].
  • The label does not limit it to a first or later treatment. It is used both in people who have never taken an ALK inhibitor and in people whose cancer grew on crizotinib[1].
  • The dose starts at 90mg a day for 7 days and then rises to 180mg a day[1].
  • The ALTA-1L trial compared it with crizotinib in people new to ALK inhibitors.
  • The median time before the cancer grew or the person died was 24.0 months on Alunbrig and 11.0 months on crizotinib[1].
  • Brigatinib was discovered by ARIAD Pharmaceuticals.
  • Takeda bought ARIAD in February 2017 and sells it in the US[2].
Follow Alunbrig by email

We'll email you when Alunbrig's FDA label changes, when the FDA acts on it, and when new trials for ALK-Positive Lung Cancer open. Unsubscribe anytime.

You'll get, for ALK-Positive Lung Cancer:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.

We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

Where Brigatinib fits

Alunbrig (brigatinib) is a once-daily ALK inhibitor pill for adults with ALK-positive lung cancer that has spread, whether or not they have taken another ALK inhibitor[1].

  • Crizotinib (Xalkori), ceritinib (Zykadia), alectinib (Alecensa) and lorlatinib (Lorbrena) are also FDA approved for ALK-positive lung cancer[13][14][11][12].
  • Ensartinib (Ensacove) is approved for people who have not taken an ALK inhibitor[10].
  • Neladalkib (Nelkarmi) received accelerated approval in November 2026 for adults with locally advanced or metastatic ALK-positive non-small cell lung cancer. It is for people already treated for advanced or metastatic disease. That earlier treatment was either alectinib as their only ALK inhibitor, or 2 or more ALK inhibitors plus platinum chemotherapy[9].
  • ALTA-1L compared Alunbrig with crizotinib in people new to ALK inhibitors, and the eXalt3 trial of ensartinib used crizotinib as its comparison too[1][10].
  • ALTA-3 compared Alunbrig with alectinib after crizotinib and found no statistically significant difference in how long the cancer was held back[6].
  • Trial Friend found no registered Phase 3 trial comparing Alunbrig with lorlatinib, ensartinib or neladalkib.
  • Anyone curious about brigatinib can ask their oncologist how its first-week lung monitoring, blood pressure checks and lab tests compare with the other ALK inhibitors open to them.

How Brigatinib works

About 3-5% of people with metastatic non-small cell lung cancer have a rearrangement in the ALK gene, according to Takeda[3]. The rearrangement joins part of ALK to another gene, most often one called EML4, and the fused ALK protein sends a constant signal that keeps the cancer cells growing[1]. Brigatinib blocks that signal by stopping ALK from switching on the proteins downstream of it[1].

Over time, tumors can change the ALK protein in ways that stop earlier drugs from working. In lab tests, brigatinib blocked cells carrying ALK plus 17 different resistance changes linked to crizotinib and other ALK inhibitors. In mice, it slowed tumors carrying the G1202R and L1196M changes[1]. Brigatinib also blocked ROS1, IGF-1R, FLT-3 and some forms of EGFR in lab tests, and it shrank ALK-driven tumors placed in the brains of mice[1].

Side effects and safety

What patients report

Alunbrig has no boxed warning, and the label lists no contraindications[1]. The label lists 10 warnings, starting with lung inflammation, high blood pressure, slow heart rate, vision problems and a rise in the muscle enzyme CPK. The others are a rise in pancreas enzymes, liver problems, high blood sugar, sun sensitivity and harm to an unborn baby[1].

Lungs: Severe, life-threatening and fatal lung inflammation (interstitial lung disease or pneumonitis) has occurred[1]. In ALTA-1L it occurred in 5.1% of people on Alunbrig, and in 2.9% it started within the first 8 days[1]. In the earlier ALTA trial it occurred in 9.1% of the group that stepped up to 180mg. In that trial, reactions within the first 9 days began a median of 2 days after starting[1].

The label says to watch for new or worse breathing symptoms such as shortness of breath or cough, especially in the first week. It also says to hold the drug while the cause is checked[1].

Blood pressure: High blood pressure occurred in 32% in ALTA-1L. In 13% it was grade 3, needing more treatment[1]. Blood pressure is brought under control before starting, then checked after 2 weeks and at least monthly[1].

Heart rate: A heart rate below 50 beats a minute occurred in 8.1% in ALTA-1L[1]. Heart rate and blood pressure are checked during treatment, more often when another medicine that slows the heart is used[1].

Eyes: Vision problems such as blurred vision, light sensitivity and flashes of light occurred in 7.4% in ALTA-1L, and the label says to report any vision symptoms[1].

Muscle enzyme: CPK, a blood test that can signal muscle damage, rose in 81% in ALTA-1L and reached grade 3 or 4 in 24%[1]. The label says to report unexplained muscle pain, tenderness or weakness[1].

Pancreas enzymes: Lipase rose in 59% and amylase in 52% in ALTA-1L, with grade 3 or 4 lipase rises in 17%[1].

Liver: AST rose in 72% and ALT in 52% in ALTA-1L, with grade 3 or 4 rises in 4.5% and 5.2%[1]. Liver tests are checked during treatment, especially in the first 3 months[1].

Blood sugar: New or worse high blood sugar occurred in 56% in ALTA-1L and was grade 3 in 7.5%[1]. Fasting blood sugar is checked before starting and from time to time after[1].

Sun: Sun sensitivity occurred in 3.7% in ALTA-1L[1]. The label advises limiting sun during treatment and for at least 5 days after the last dose. It advises a hat, protective clothing and broad-spectrum sunscreen and lip balm of SPF 30 or higher[1].

Pregnancy: Alunbrig can harm an unborn baby, and a pregnancy test is done before starting for anyone who could become pregnant[1]. The label calls for effective birth control during treatment and for at least 4 months after the last dose. It also calls for male patients with partners who could become pregnant to use birth control for at least 3 months after[1]. Breastfeeding is not advised during treatment and for 1 week after, and Alunbrig may reduce male fertility[1].

Most common: In ALTA-1L the most common side effects on Alunbrig were diarrhea (53%), rash (40%), cough (35%) and tiredness (32%). Other common ones were high blood pressure (32%), nausea (30%), muscle pain (28%) and shortness of breath (25%)[1]. Serious side effects occurred in 33%, most often pneumonia and lung inflammation, and side effects were fatal in 2.9%[1]. Of the 136 people treated, 13% stopped Alunbrig for good because of side effects and 38% needed a lower dose, most often for a rise in CPK[1].

This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.

Taking Brigatinib

The label dose is 90mg by mouth once a day for the first 7 days, then 180mg once a day, with or without food[1]. Tablets come in 30mg, 90mg and 180mg strengths and are swallowed whole, not crushed or chewed[1]. A one-month starter carton holds 7 tablets of 90mg and 23 tablets of 180mg[1]. After a missed dose or vomiting, no extra dose is taken, and the next dose is taken at the usual time[1].

When Alunbrig is paused for 14 days or longer for a reason other than side effects, it restarts at 90mg a day for 7 days before going back up[1].

For side effects, the doctor may pause Alunbrig or lower the 180mg dose to 120mg, then 90mg, then 60mg once a day[1]. A lowered dose is not raised again, and Alunbrig is stopped for good in people who cannot tolerate 60mg[1].

Before starting: Blood pressure is brought under control, fasting blood sugar is checked and a pregnancy test is done for anyone who could become pregnant[1].

Other medicines: Brigatinib is broken down mainly by the enzymes CYP2C8 and CYP3A4[1]. The label says to avoid strong and moderate CYP3A inhibitors, which raise brigatinib levels. It also says to avoid strong and moderate CYP3A inducers, which lower them, and gives dose changes when one cannot be avoided[1].

Liver and kidneys: The dose is lowered for severe liver impairment (Child-Pugh C) and for severe kidney impairment[1].

Availability and cost

No generic available

Only available as the brand-name product.

Help paying for Alunbrig

With private insurance, the drugmaker's copay card can lower what you pay for Alunbrig. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE, but charity funds often can. None of the 4 charity funds for ALK-Positive Lung Cancer were open on November 18, 2026. Pick your insurance below to see which offers fit you.

Your insurance
From the drugmaker
Alunbrig (Brigatinib)
Some details not published
  • Copay help

    Takeda Oncology Co-pay Assistance Program: eligible commercially insured patients may pay as little as $0 per prescription. Must be 18 or older and live in the US or a US territory, with private insurance that does not cover the full cost. Not valid when any part of the prescription can be paid by Medicare, Medicare Advantage, Medigap, Medicaid, DoD, VA, TRICARE, Puerto Rico Government Insurance or a state assistance program. Valid for 12 months and renewable. No income requirement. The page gives no annual maximum.

    For: private insurance · source
  • Insurance and case manager help

    Here2Assist case managers help with insurance coverage, finding financial assistance, choosing a specialty pharmacy and follow-up calls. For people with Medicare, Medicaid or TRICARE, Takeda points to nonprofits, social workers and Medicare Part D Extra Help. Call 1-844-817-6468, Option 2, Monday to Friday, 8 AM to 8 PM ET. Enrollment form fax 1-844-269-3038.

    For: private insurance, Medicare, Medicaid, no insurance · source

Good to know: Copay and case manager terms read on alunbrig.com/here2assist on November 18, 2026. Third-party listings describe a Takeda Oncology Patient Assistance Program (free drug) and a RapidStart free first-month supply for Alunbrig, but neither alunbrig.com nor here2assist.com showed their terms when read, and they are left out until Takeda's own page confirms them.

Checked on the drugmaker's official pages on November 18, 2026. Programs change; confirm with the program before you rely on it.

Charity funds for ALK-Positive Lung Cancer

No charity fund for this condition is open right now. Funds reopen when they receive new donations; the foundations let you sign up to be told when one opens.

Status as each foundation showed it on November 18, 2026.

Every program and charity fund for ALK-Positive Lung Cancer →

More ways to get help paying for treatment →

Insurance said no? Your Insurer Denied a Rare Disease Drug and Fewer Than 1 in 100 People Appeal, So Here Is the Playbook · 14 min read

Clinical trial results

ALTA-1L (NCT02737501) was a randomized, open-label Phase 3 trial of 275 adults with advanced ALK-positive lung cancer who had not taken an ALK inhibitor. It compared Alunbrig (137 people) with crizotinib 250mg twice a day (138 people)[1][4]. People could have had 1 earlier chemotherapy, people with stable brain metastases could join, and people on crizotinib could switch to Alunbrig if their cancer grew[1]. Results judged by reviewers who did not know the treatment, from the label[1]:

  • Time before the cancer grew or the person died: median 24.0 months on Alunbrig and 11.0 months on crizotinib (hazard ratio 0.49)
  • Tumors shrank in 74% on Alunbrig and 62% on crizotinib
  • Responses lasted a median of 33.1 months on Alunbrig and 13.8 months on crizotinib
  • In people with measurable brain metastases, brain tumors shrank in 78% of 18 on Alunbrig and 26% of 23 on crizotinib
  • At the final overall survival analysis, about 3 years after the last person enrolled, 41 people had died on Alunbrig and 51 on crizotinib. Median survival was not reached in either group

ALTA (NCT02094573) tested 2 doses of Alunbrig in 222 adults whose cancer grew on crizotinib[1][5]. Tumors shrank in 48% of 112 people on 90mg a day and 53% of 110 people on the 90mg to 180mg schedule. Responses lasted a median of 13.8 months in each group[1]. Brain tumors shrank in 42% of 26 and 67% of 18 people with measurable brain metastases[1]. ALTA was the basis for the 2017 accelerated approval[2].

ALTA-3 (NCT03596866) was a randomized Phase 3 trial comparing Alunbrig (125 people) with alectinib (123 people) in adults whose cancer grew on crizotinib[6]. Results posted on ClinicalTrials.gov were judged by reviewers who did not know the treatment. They showed a median time before the cancer grew or the person died of 19.3 months on Alunbrig and 19.2 months on alectinib.

The difference was not statistically significant (hazard ratio 0.97)[6]. Overall survival, a secondary measure, also showed no statistically significant difference. Its hazard ratio of 1.59 pointed numerically toward a higher risk of death on Alunbrig (95% confidence interval 0.96 to 2.65)[6]. Tumors shrank in 52.0% on Alunbrig and 61.0% on alectinib as judged by the independent reviewers, and in 40.8% and 56.1% as judged by the trial doctors[6].

Development history

ARIAD Pharmaceuticals discovered brigatinib, tested it under the code AP26113, and began the ALTA trial in June 2014[5][2]. Takeda bought ARIAD in February 2017[2]. The FDA granted accelerated approval on April 28, 2017 for ALK-positive metastatic lung cancer, after giving brigatinib Breakthrough Therapy and Orphan Drug designations. The approval was based on tumor response rate and how long responses lasted[2].

Takeda described that first use as people whose cancer had grown on crizotinib or who could not tolerate it[3]. ALTA-1L began in May 2016, and its first results were published in the New England Journal of Medicine in 2018[4][7]. On May 22, 2020 the FDA expanded the label to include people who had not taken an ALK inhibitor, based on ALTA-1L[3]. The current label covers adults with ALK-positive metastatic non-small cell lung cancer without naming a line of treatment[1].

Ask anything about Brigatinib
AI-powered answers from clinical trial databases, FDA reports, and medical literature
Start withor ask

Explore ALK-Positive Lung Cancer trials

Other ALK-Positive Lung Cancer treatments

Common questions about Brigatinib

▸What is Brigatinib (Alunbrig)?

Alunbrig (brigatinib) is a pill taken once a day for adults with ALK-positive non-small cell lung cancer, found with an FDA-approved test. It is for cancer that has spread to other parts of the body (metastatic)[1]. The label does not limit it to a first or later treatment. It is used both in people who have never taken an ALK inhibitor and in people whose cancer grew on crizotinib[1]. The dose starts at 90mg a day for 7 days and then rises to 180mg a day[1]. The ALTA-1L trial compared it with crizotinib in people new to ALK inhibitors. The median time before the cancer grew or the person died was 24.0 months on Alunbrig and 11.0 months on crizotinib[1]. Brigatinib was discovered by ARIAD Pharmaceuticals. Takeda bought ARIAD in February 2017 and sells it in the US[2].

▸How does Brigatinib work?

About 3-5% of people with metastatic non-small cell lung cancer have a rearrangement in the ALK gene, according to Takeda[3]. The rearrangement joins part of ALK to another gene, most often one called EML4, and the fused ALK protein sends a constant signal that keeps the cancer cells growing[1]. Brigatinib blocks that signal by stopping ALK from switching on the proteins downstream of it[1].

Over time, tumors can change the ALK protein in ways that stop earlier drugs from working. In lab tests, brigatinib blocked cells carrying ALK plus 17 different resistance changes linked to crizotinib and other ALK inhibitors. In mice, it slowed tumors carrying the G1202R and L1196M changes[1]. Brigatinib also blocked ROS1, IGF-1R, FLT-3 and some forms of EGFR in lab tests, and it shrank ALK-driven tumors placed in the brains of mice[1].

▸What are the side effects of Brigatinib?

Alunbrig has no boxed warning, and the label lists no contraindications[1]. The label lists 10 warnings, starting with lung inflammation, high blood pressure, slow heart rate, vision problems and a rise in the muscle enzyme CPK. The others are a rise in pancreas enzymes, liver problems, high blood sugar, sun sensitivity and harm to an unborn baby[1].

Lungs: Severe, life-threatening and fatal lung inflammation (interstitial lung disease or pneumonitis) has occurred[1]. In ALTA-1L it occurred in 5.1% of people on Alunbrig, and in 2.9% it started within the first 8 days[1]. In the earlier ALTA trial it occurred in 9.1% of the group that stepped up to 180mg. In that trial, reactions within the first 9 days began a median of 2 days after starting[1]. The label says to watch for new or worse breathing symptoms such as shortness of breath or cough, especially in the first week. It also says to hold the drug while the cause is checked[1].

Blood pressure: High blood pressure occurred in 32% in ALTA-1L. In 13% it was grade 3, needing more treatment[1]. Blood pressure is brought under control before starting, then checked after 2 weeks and at least monthly[1].

Heart rate: A heart rate below 50 beats a minute occurred in 8.1% in ALTA-1L[1]. Heart rate and blood pressure are checked during treatment, more often when another medicine that slows the heart is used[1].

Eyes: Vision problems such as blurred vision, light sensitivity and flashes of light occurred in 7.4% in ALTA-1L, and the label says to report any vision symptoms[1].

Muscle enzyme: CPK, a blood test that can signal muscle damage, rose in 81% in ALTA-1L and reached grade 3 or 4 in 24%[1]. The label says to report unexplained muscle pain, tenderness or weakness[1].

Pancreas enzymes: Lipase rose in 59% and amylase in 52% in ALTA-1L, with grade 3 or 4 lipase rises in 17%[1].

Liver: AST rose in 72% and ALT in 52% in ALTA-1L, with grade 3 or 4 rises in 4.5% and 5.2%[1]. Liver tests are checked during treatment, especially in the first 3 months[1].

Blood sugar: New or worse high blood sugar occurred in 56% in ALTA-1L and was grade 3 in 7.5%[1]. Fasting blood sugar is checked before starting and from time to time after[1].

Sun: Sun sensitivity occurred in 3.7% in ALTA-1L[1]. The label advises limiting sun during treatment and for at least 5 days after the last dose. It advises a hat, protective clothing and broad-spectrum sunscreen and lip balm of SPF 30 or higher[1].

Pregnancy: Alunbrig can harm an unborn baby, and a pregnancy test is done before starting for anyone who could become pregnant[1]. The label calls for effective birth control during treatment and for at least 4 months after the last dose. It also calls for male patients with partners who could become pregnant to use birth control for at least 3 months after[1]. Breastfeeding is not advised during treatment and for 1 week after, and Alunbrig may reduce male fertility[1].

Most common: In ALTA-1L the most common side effects on Alunbrig were diarrhea (53%), rash (40%), cough (35%) and tiredness (32%). Other common ones were high blood pressure (32%), nausea (30%), muscle pain (28%) and shortness of breath (25%)[1]. Serious side effects occurred in 33%, most often pneumonia and lung inflammation, and side effects were fatal in 2.9%[1]. Of the 136 people treated, 13% stopped Alunbrig for good because of side effects and 38% needed a lower dose, most often for a rise in CPK[1].

▸How is Brigatinib taken?

The label dose is 90mg by mouth once a day for the first 7 days, then 180mg once a day, with or without food[1]. Tablets come in 30mg, 90mg and 180mg strengths and are swallowed whole, not crushed or chewed[1]. A one-month starter carton holds 7 tablets of 90mg and 23 tablets of 180mg[1]. After a missed dose or vomiting, no extra dose is taken, and the next dose is taken at the usual time[1]. When Alunbrig is paused for 14 days or longer for a reason other than side effects, it restarts at 90mg a day for 7 days before going back up[1].

For side effects, the doctor may pause Alunbrig or lower the 180mg dose to 120mg, then 90mg, then 60mg once a day[1]. A lowered dose is not raised again, and Alunbrig is stopped for good in people who cannot tolerate 60mg[1].

Before starting: Blood pressure is brought under control, fasting blood sugar is checked and a pregnancy test is done for anyone who could become pregnant[1].

Other medicines: Brigatinib is broken down mainly by the enzymes CYP2C8 and CYP3A4[1]. The label says to avoid strong and moderate CYP3A inhibitors, which raise brigatinib levels. It also says to avoid strong and moderate CYP3A inducers, which lower them, and gives dose changes when one cannot be avoided[1].

Liver and kidneys: The dose is lowered for severe liver impairment (Child-Pugh C) and for severe kidney impairment[1].

▸Is Brigatinib FDA approved?

Yes, Brigatinib (Alunbrig) is FDA approved (2017) for the treatment of ALK-Positive Lung Cancer.

▸Why does Alunbrig start at 90mg and then go to 180mg?

The label sets a starting dose of 90mg once a day for the first 7 days, then 180mg once a day.

First week: In ALTA-1L, lung inflammation began within the first 8 days in 2.9% of people, and the label says to watch breathing symptoms most closely in that week.

If lung symptoms appear early: The doctor holds Alunbrig and does not raise the dose to 180mg if lung inflammation is suspected.

After a pause: A break of 14 days or longer for reasons other than side effects means restarting at 90mg for 7 days.

Starter pack: A one-month carton holds 7 tablets of 90mg and 23 of 180mg.

More: ALK-positive lung cancer treatments compared

Source: [ALUNBRIG (BRIGATINIB) TABLET, FILM COATED ALUNBRIG (BRIGATINIB) KIT [TAKEDA PHARMACEUTICALS AMERICA, INC.]](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fe9ff20-d402-41f3-bc1e-7002ea7007db)

▸What are the side effects of brigatinib?

Diarrhea, rash, cough, tiredness, high blood pressure and nausea were the most common side effects of Alunbrig in ALTA-1L.

Lungs: Lung inflammation occurred in 5.1%, often in the first week.

Lab changes: CPK, a muscle enzyme, rose in 81%, lipase in 59%, AST in 72% and blood sugar in 56%.

Blood pressure: High blood pressure occurred in 32%, with checks after 2 weeks and at least monthly.

Other warnings: Slow heart rate, vision problems, sun sensitivity and harm to an unborn baby.

Stopping: Of 136 people, 13% stopped Alunbrig for good because of side effects, and 38% needed a lower dose.

Boxed warning: None.

Source: [ALUNBRIG (BRIGATINIB) TABLET, FILM COATED ALUNBRIG (BRIGATINIB) KIT [TAKEDA PHARMACEUTICALS AMERICA, INC.]](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fe9ff20-d402-41f3-bc1e-7002ea7007db)

▸How does brigatinib compare with alectinib?

ALTA-3 is the one head-to-head trial of brigatinib and alectinib, in people whose cancer grew on crizotinib. It found no statistically significant difference in the time before the cancer grew.

Main result: The median time before the cancer grew or the person died was 19.3 months on brigatinib and 19.2 months on alectinib, a hazard ratio of 0.97.

Survival: Overall survival showed no statistically significant difference, with a hazard ratio of 1.59 that pointed numerically toward a higher risk of death on brigatinib.

Response: Tumors shrank in 52.0% on brigatinib and 61.0% on alectinib by independent review, and in 40.8% and 56.1% by the trial doctors.

Size: The trial enrolled 248 people, 125 on brigatinib and 123 on alectinib.

Not tested: ALTA-3 did not include people who had never taken an ALK inhibitor.

Source: ClinicalTrials.gov NCT03596866

▸How much does Alunbrig cost with insurance?

Takeda says people with commercial insurance may pay as little as $0 per prescription through the Takeda Oncology Co-pay Assistance Program, and the label gives no price.

Who qualifies: Adults 18 and older in the US or a US territory with private insurance that does not cover the full cost.

Not eligible: People whose prescription is covered in whole or in part by Medicare, Medicaid, TRICARE, the VA or another government program.

Government insurance: Takeda points to nonprofits, social workers and Medicare Part D Extra Help.

Contact: Takeda Oncology Here2Assist, 1-844-817-6468, Option 2, Monday to Friday, 8 AM to 8 PM ET.

Source: Financial Assistance With the Takeda Oncology Here2Assist® Program

Sources and references

Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.

  1. U.S. National Library of Medicine, DailyMed · 2026-01. ALUNBRIG (BRIGATINIB) TABLET, FILM COATED ALUNBRIG (BRIGATINIB) KIT [TAKEDA PHARMACEUTICALS AMERICA, INC.]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fe9ff20-d402-41f3-bc1e-7002ea7007db
  2. Takeda Pharmaceutical Company Limited · 2017-04-28. Takeda Announces FDA Accelerated Approval of ALUNBRIG™ (brigatinib). https://www.takeda.com/newsroom/newsreleases/2017/alunbrig-fda-approval/
  3. Takeda Pharmaceutical Company Limited · 2020-05-22. U.S. FDA Approves Takeda's ALUNBRIG® (brigatinib) as a First-Line Treatment Option for Patients Diagnosed with Rare and Serious Form of Lung Cancer. https://www.takeda.com/newsroom/newsreleases/2020/us-fda-approves-takedas-alunbrig-brigatinib-as-a-first-line-treatment-option-for-patients-diagnosed-with-rare-and-serious-form-of-lung-cancer/
  4. ClinicalTrials.gov · 2026-11-18. ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants. https://clinicaltrials.gov/study/NCT02737501
  5. ClinicalTrials.gov · 2026-11-18. A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib. https://clinicaltrials.gov/study/NCT02094573
  6. ClinicalTrials.gov · 2026-11-18. A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer. https://clinicaltrials.gov/study/NCT03596866
  7. The New England Journal of Medicine · 2018-11-22. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.. https://pubmed.ncbi.nlm.nih.gov/30280657/
  8. Takeda Pharmaceuticals America, Inc. · 2026-11-18. Financial Assistance With the Takeda Oncology Here2Assist® Program. https://www.alunbrig.com/here2assist
  9. Nuvalent, Inc. · 2026-11. NELKARMI (neladalkib) tablets, for oral use: Full Prescribing Information. https://nuvalent.com/pdfs/nelkarmi-full-prescribing-information.pdf
  10. U.S. National Library of Medicine, DailyMed · 2026-02. ENSACOVE (ENSARTINIB) CAPSULE [XCOVERY HOLDINGS, INC.]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e1b2f79-678a-472a-b924-66909c8a4b2e
  11. U.S. National Library of Medicine, DailyMed · 2026-08. ALECENSA (ALECTINIB HYDROCHLORIDE) CAPSULE [GENENTECH, INC.]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42c49deb-713b-427a-9670-08af08adcffb
  12. U.S. National Library of Medicine, DailyMed · 2026-06. LORBRENA (LORLATINIB) TABLET, FILM COATED [PFIZER LABORATORIES DIV PFIZER INC]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b34d62d-e02a-4af3-bc0d-1571dd4ee76d
  13. U.S. National Library of Medicine, DailyMed · 2026-11. XALKORI (CRIZOTINIB) CAPSULE XALKORI (CRIZOTINIB) CAPSULE, COATED PELLETS [PFIZER LABORATORIES DIV PFIZER INC]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a51b0de-47d6-455e-a94c-d2c737b04ff7
  14. U.S. National Library of Medicine, DailyMed · 2026-10. ZYKADIA (CERITINIB) TABLET, FILM COATED [NOVARTIS PHARMACEUTICALS CORPORATION]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fff5d805-4ffd-4e8e-8e63-6f129697563e

This page is for informational purposes only and does not constitute medical advice. Drug information is sourced from public databases and peer-reviewed literature and may not reflect the most recent updates. Always discuss treatment options with your healthcare provider. Last reviewed: November 2026.

Follow Alunbrig by email

We'll email you when Alunbrig's FDA label changes, when the FDA acts on it, and when new trials for ALK-Positive Lung Cancer open. Unsubscribe anytime.

You'll get, for ALK-Positive Lung Cancer:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site